12-week, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine extended-release (ER) in patients with overactive bladder.

Trial Profile

12-week, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine extended-release (ER) in patients with overactive bladder.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Fesoterodine; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Mar 2011 Bladder diary and patient-reported outcomes for the first week of treatment published in the Current Medical Research and Opinion.
    • 01 Jan 2010 Primary endpoint 'Frequency of urgency episodes' has been met.
    • 01 Jan 2010 Results published in BJU International.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top